Previous 10 | Next 10 |
Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch PR Newswire WASHINGTON , Dec. 16, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) toda...
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation PR Newswire WASHINGTON , Dec. 13, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its HETLIOZ ® ANDA Litigation. Vanda h...
Update 12pm: Updates shares. Vanda Pharmaceuticals ( NASDAQ: VNDA ) plummeted 23% after a loss in patent case for its sleep-wake disorder drug Hetlioz. All four claims in the case were found to be invalid, according to the court opinion. "I find that Defendants' ANDA p...
Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety PR Newswire WASHINGTON , Dec. 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase I...
The following slide deck was published by Vanda Pharmaceuticals Inc. in conjunction with this event. For further details see: Vanda Pharmaceuticals (VNDA) Investor Presentation -Slideshow
Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences PR Newswire WASHINGTON , Nov. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following ...
Vanda Pharmaceuticals Inc. (VNDA) Q3 2022 Earnings Conference Call November 2, 2022 16:30 ET Company Participants Kevin Moran - Senior Vice President & Chief Financial Officer Mihael Polymeropoulos - President & Chief Executive Officer Tim Williams - Gene...
Vanda Pharmaceuticals press release ( NASDAQ: VNDA ): Q3 GAAP EPS of $0.06. Revenue of $65.32M (-6.8% Y/Y). Cash, cash equivalents and marketable securities (Cash) was $454.8 million as of September 30, 2022, representing an increase to Cash of $13.9 million, or 3%, co...
Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results PR Newswire Q3 2022 total revenues were $65.3 million Total revenues in the first nine months of 2022 were $189.9 million Vanda provides update on pipeline advancements and upc...
Vanda Pharmaceuticals ( NASDAQ: VNDA ) is scheduled to announce Q3 earnings results on Wednesday, November 2nd, after market close. The consensus EPS Estimate is $0.09 (-35.7% Y/Y) and the consensus Revenue Estimate is $71M (+1.3% Y/Y). Over the last 3 months, Revenue ...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...